The Synergistic Anticancer Effect of Pitavastatin and Metformin Against BT-20 Breast Cancer Cell Line Types

Background: Breast cancer ranks second in terms of all malignancies worldwide, making it one of the most common cancers. Treatment efforts for breast cancer have several disadvantages, including cytotoxic side effects and multidrug resistance. As a result, a shift toward more effective drugs with fewer side effects is required. Studies have recently demonstrated the efficacy of both Pitavastatin and Metformin against cancer cells, and we found that their combination has a significant influence against breast cancer cells when compared to utilizing either drug alone. Methods: The cytotoxicity of Metformin and Pitavastatin on BT-20 breast cancer cells was evaluated using the MTT test. A trypan blue assay was used to evaluate the combined treatment's anti-proliferative effects. Results: According to the study's findings, BT-20 cell viability was decreased by pitavastatin and metformin treatments alone in a concentration- and time-dependent manner. However, combining the two drugs resulted in a greater antiproliferative impact on BT-20 cells. Trypan blue results showed that combination drugs kill BT-20 cells more than single treatments. Conclusion: The results suggest that the combination of Pitavastatin and Metformin has a synergistic anticancer effect against BT-20 breast cancer cells.